BioCardia (BCDA) FCF Margin (2011 - 2024)
BioCardia's (BCDA) quarterly FCF Margin came in at 43833.33% in Q2 2024, down 3650078.0% year-over-year from N/an in Q3 2023, and down 1475.71% quarter-over-quarter from 2781.82% in Q1 2024.
Powered by 
Analysis
BioCardia (BCDA) FCF Margin (2011 - 2024) Analysis & Trends
BioCardia (BCDA) has reported FCF Margin for 12 consecutive years, with 43833.33% the latest figure, recorded in Q2 2024.
- On a quarterly basis, FCF Margin fell 3650078.0% year-over-year to 43833.33% in Q2 2024; TTM through Mar 2025 was 266000.0%, a 26408846.0% decrease from a year earlier, with the FY2024 full-year figure at 13606.9%, down 1151340.0% from the prior year.
- FCF Margin was 43833.33% for Q2 2024 at BioCardia, down from 2781.82% in the prior quarter.
- Over five years, FCF Margin peaked at 274.13% in Q2 2022 and troughed at 43833.33% in Q2 2024.
- A 5-year average of 7166.77% and a median of 4172.46% in 2021 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin surged 1034329 bps in 2021 and slumped 3650078 bps in 2024, its largest moves.
- Over 5 years, FCF Margin stood at 7428.26% in 2020, then jumped by 49 bps to 3817.72% in 2021, then gained by 26 bps to 2829.25% in 2022, then tumbled by 403 bps to 14238.46% in 2023, then tumbled by 208 bps to 43833.33% in 2024.
- The last three FCF Margin figures came in at 43833.33% (Q2 2024), 2781.82% (Q1 2024), and 14238.46% (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -13,981.63% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 18.67% |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -43,833.33% |
| Mar 31, 2024 | -2,781.82% |
| Dec 31, 2023 | -14,238.46% |
| Sep 30, 2023 | -675.63% |
| Jun 30, 2023 | -7,332.56% |
| Mar 31, 2023 | -4,015.63% |
| Dec 31, 2022 | -2,829.25% |
| Sep 30, 2022 | -952.83% |
| Jun 30, 2022 | -274.13% |
| Mar 31, 2022 | -4,903.33% |
| Dec 31, 2021 | -3,817.72% |
| Sep 30, 2021 | -324.36% |
| Jun 30, 2021 | -4,192.75% |
| Mar 31, 2021 | -4,152.17% |
| Dec 31, 2020 | -7,428.26% |
| Sep 30, 2020 | -10,667.65% |
| Jun 30, 2020 | -8,692.59% |
| Mar 31, 2020 | -7,889.47% |
| Dec 31, 2019 | -1,515.35% |
| Sep 30, 2019 | -769.07% |